^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSLN positive

    i
    Other names: MSLN, CAK1, MPF, Mesothelin
    Entrez ID:
    10232
    Related biomarkers:
    Expression
    Others
    12ms
    NCI-2018-01503: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=96, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    Avastin (bevacizumab) • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • anetumab ravtansine (BAY 94-9343)
    1year
    Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. (PubMed, Clin Transl Med)
    Activated hYP218 CAR T cells persist in the tumour microenvironment and retain their cytotoxic activity. Addition of pembrolizumab in larger tumours enhance CAR T cell efficacy.
    Journal • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD69 (CD69 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    MSLN expression • MSLN positive
    |
    Keytruda (pembrolizumab)
    1year
    Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study. (PubMed, Genome Med)
    Our study highlights the safety and therapeutic efficacy of multiple-chain DAP-CAR-T cell therapy targeting MSLN to treat patients with ovarian cancer and mesothelioma.
    P1 data • Journal • CAR T-Cell Therapy • IO biomarker
    |
    MSLN (Mesothelin) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    |
    MSLN expression • MSLN positive
    1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Recruiting, Xinqiao Hospital of Chongqing | Suspended --> Recruiting
    Enrollment open • CAR T-Cell Therapy • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    1year
    Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=20, Suspended, Xinqiao Hospital of Chongqing | Recruiting --> Suspended
    Trial suspension
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    cyclophosphamide • TC-A101
    over1year
    Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects. (PubMed, Pharmacol Res)
    IL12R54 also upregulated CXCR6 expression in the T cells through the NF-κB pathway, which facilitated T cell infiltration and persistence in the tumor tissues. In summary, the studies provide a good therapeutic option for the clinical treatment of solid tumors.
    Journal • Adverse events • CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • MSLN (Mesothelin) • CXCR6 (C-X-C Motif Chemokine Receptor 6)
    |
    MSLN positive
    almost2years
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=36, Active, not recruiting, TCR2 Therapeutics | Recruiting --> Active, not recruiting | N=175 --> 36 | Trial completion date: Apr 2026 --> Nov 2028 | Trial primary completion date: Jul 2024 --> Nov 2028
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    almost2years
    A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, TCR2 Therapeutics | Trial completion date: Dec 2027 --> Oct 2028 | Trial primary completion date: Nov 2023 --> Oct 2028
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    cyclophosphamide • fludarabine IV • TC-510
    almost2years
    Enhanced Expression of Glycolytic Enzymes and Succinate Dehydrogenase Complex Flavoprotein Subunit A by Mesothelin Promotes Glycolysis and Mitochondrial Respiration in Myeloblasts of Acute Myeloid Leukemia. (PubMed, Int J Mol Sci)
    The collective results demonstrate that mesothelin induces metabolic changes in leukemia cells, facilitating the acquisition of a rapid supply of ATP for proliferation in AML. Therefore, the targeting of mesothelin presents a potentially promising approach to mitigating the progression of AML through the inhibition of glycolysis and mitochondrial respiration in myeloid cells.
    Journal
    |
    MSLN (Mesothelin) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A)
    |
    MSLN expression • MSLN positive
    almost2years
    NCI10208: Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • ABP 206 (nivolumab biosimilar)
    almost2years
    Clinical Significance Of Mesothelin Expression And Its Correlation With HER2 In Gynecologic Carcinosarcoma (ESGO 2024)
    In this study, MSLN expression is widely observed in UCS. Moreover, high-MSLN expression is a favorable prognostic factor for UCS, which could be a promising therapeutic target, regardless of HER2 expression. This study was published in the Journal of Gynecologic Oncology.
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin)
    |
    HER-2 negative • HER-2 expression • MSLN expression • MSLN positive
    |
    VENTANA MSLN (SP74) ASSAY
    almost2years
    Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2027 --> Dec 2024 | Trial primary completion date: Dec 2026 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    MSLN (Mesothelin)
    |
    MSLN expression • MSLN positive
    |
    LMB-100